Intersect ENT (XENT) Misses Q1 EPS by 9c, Revenues Beat; Raises FY21 Revenues Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Intersect ENT Reports First Quarter 2021 Financial Results
May 10, 2021 7:00 AM EDTIncreases 2021 Revenue Guidance to $117 Million to $121 Million
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today reported financial results for the first quarter ended March 31, 2021.
First Quarter 2021 Overview
Revenue of $24.3 million in the first quarter of 2021, up 23%, compared to $19.8 million in the first quarter of 2020.Strong quarterly SINUVA revenue of $2.4 million.
Global Balloon and Navigation portfolio generated revenue of $1.5 million.
Cash, cash equivalents, restricted cash, and... More
